| 货号 | 15895-10mg |
| 描述 | A number of 17-aryl trinor and 16-aryloxy tetranor prostaglandin F2α derivatives have been approved for the treatment of glaucoma.1,2,3 These “ring” prostaglandin (PG) analogs have improved efficacy over the PGs with an n-alkyl lower side chain. Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects.4 17-trifluoromethylphenyl-13,14-dihydro trinor PGF1α(17-TFM-PGF1α) is a typical “ring” analog reminiscent of the trifluoromethyl-phenoxy ring of Travoprost. The a chain of 17-TFM-PGF1α is saturated, making this compound a formal member of the one-series PGs. Recent work has shown that in the “ring” series of analogs, this modification has little impact on FP receptor binding.5 As an ocular hypotensive agent, it is expected that 17-TFM-PGF1α would act very much like the free acid of latanoprost. |
| 别名 | 17-TFM-PGF1α; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Woodward, D.F.,Krauss, A.H.P.,Chen, J., et al. The pharmacology of Bimatoprost (Lumigan™). Survey of Ophthalmology 45, S337-S345 (2001). 2.Stjernschantz, J.W. From PGF2α-isopropyl ester to latanoprost: A review of the development of xalatan. The proper lecture. Investigative Ophthalmology & Visual Science 42(6), 1134-1145 (2001). 3.Sorbera, L.A. and Castañer, J. Travoprost. Drugs of the Future 25, 41-45 (2000). 4.Resul, B.,Stjernschantz, J.,No, K., et al. Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents. Journal of Medicinal Chemistry 36, 243-248 (1993). 5.deLong, M.A.,Amburgey, J.,Taylor, C., et al. Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues. Bioorganic & Medicinal Chemistry Letters 10, 1519-1522 (2000). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 460.5 |
| 分子式 | C24H35F3O5 |
| CAS号 | 1027401-98-4 |
| 稳定性 | ≥ 1 year |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |